Do genetic variants change GLP-1 weight loss?

Genetics may slightly affect GLP-1 response and side effects

Scientists identified genetic variants associated with slightly greater weight loss and with the incidence of side effects in people taking glucagon-like peptide-1 (GLP-1) drugs such as Wegovy and Mounjaro. The work matters because it addresses a practical problem clinicians face with obesity and weight-loss medicines: people do not respond the same way.

Instead of claiming that genetics can predict an individual’s outcome with certainty, the report frames the associations as modest—linked to “slightly greater” weight loss and to side-effect occurrence. That means genetics could eventually help refine expectations and risk management, but it is unlikely to fully determine outcomes on its own.

The story fits into a broader theme in the GLP-1 space: multiple studies are exploring why some patients lose substantially more weight than others and why some experience more nausea or other adverse effects. If replicated, genetic markers could inform counseling—such as which patients might be more likely to achieve stronger weight reduction or may need closer side-effect monitoring.

However, the excerpt does not provide key details that would determine how immediately useful the findings are, including which specific variants were implicated, how large the outcome differences were, whether results differed across drug types or dosing strategies, or whether clinicians tested the findings in prospective trials.

For now, the takeaway is that the biological differences behind obesity treatment responses are not purely “personal responsibility” or lifestyle effects. Even within the same drug class, genetics can contribute to both efficacy and tolerability.

As additional evidence emerges, the most likely near-term impact is incremental: better understanding of variability in GLP-1 outcomes, and—over time—more personalized guidance about expected benefits and side-effect risk.